Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Heshuxiaoji Pill is a Traditional Chinese Medicine (TCM) formulation developed by The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University. It is primarily investigated for the treatment of hepatitis B virus (HBV)-related primary liver cancer (hepatocellular carcinoma), specifically targeting patients in the middle and advanced stages (BCLC stages B-D). The pill is utilized as part of an integrated traditional Chinese and Western medicine approach to optimize standard treatment protocols, with the goal of extending overall survival and improving clinical outcomes. As a complex herbal preparation, it is believed to exert multi-target therapeutic effects, including anti-tumor activity and hepatoprotective properties, although its specific molecular targets are not typically defined in the same manner as conventional targeted therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Heshuxiaoji Pill.